Generic Name

C-11

FDA approval date: September 12, 2012
Classification: Radioactive Diagnostic Agent
Form: Injection

What is C-11?

Choline C 11 Injection is indicated for positron emission tomography imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography or magnetic resonance imaging . In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration. Limitation of U se: 11 C-choline PET imaging is not a replacement for histologic verification of recurrent prostate cancer. Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography or magnetic resonance imaging. In these patients, 11 C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation. Suspected prostate recurrence is based upon elevated blood prostate specific antigen levels following initial therapy. In clinical studies, images were produced with PET/CT coregistration. Limitation of U se: 11 C-choline PET imaging is not a replacement for histologic verification of recurrent prostate cancer .

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Pilot Study of a Multi-System Analysis of Opioid Receptor Binding

Summary: This study will enroll up to 60 adults (including 30 females and 30 males) in three cohorts of up to 20 subjects each. In all three groups, \[11C\]carfentanil whole-body PET imaging will be used to examine the central nervous system (CNS) and broader systemic opioid binding in an initial scan session. In the two groups not receiving standard of care medication assisted treatment (MAT) for opioid u...

Neuroinflammation, White Matter Integrity, AD Biomarkers and Pathology in Corticobasal Syndrome

Summary: The primary goal of this study is to investigate inflammation and white matter damage in corticobasal syndrome and determine whether these processes are related to each other. The investigator's will address our goal by using neuroimaging and blood plasma biomarkers, as well as molecular pathology.

Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study

Summary: This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.